The Application Notebook
Opiate abuse is drastically on the rise in the United States. In addition to traditional naturally occurring opiate compounds, forensic toxicologists also need to be able to rapidly identify synthetic opioid-like drugs. A rapid, three-step solid-phase extraction (SPE) procedure for the identification and quantification of fentanyl and its major urinary metabolite norfentanyl, in addition to four “designer” compounds, U-47700, W-18, W-15, and furanyl fentanyl, is presented here. As a result of the rapid use and abuse of fentanyl in medical and recreational settings, respectively, it is important to develop a method that can accurately extract this Schedule II drug from any other novel compounds that may be present.
Danielle Mackowsky, UCT, LLC
Summary
Opiate abuse is drastically on the rise in the United States. In addition to traditional naturally occurring opiate compounds, forensic toxicologists also need to be able to rapidly identify synthetic opioid-like drugs. A rapid, three-step solid-phase extraction (SPE) procedure for the identification and quantification of fentanyl and its major urinary metabolite norfentanyl, in addition to four “designer” compounds, U-47700, W-18, W-15, and furanyl fentanyl, is presented here. As a result of the rapid use and abuse of fentanyl in medical and recreational settings, respectively, it is important to develop a method that can accurately extract this Schedule II drug from any other novel compounds that may be present.
Procedure
1. Sample Pretreatment:
To 1 mL of urine sample, add 1 mL of 100 mM phosphate buffer (pH = 6) and an appropriate amount of internal standard.
2. Sample Extraction:
Apply the sample to the SPE cartridge (if required, use a low vacuum to draw the sample through at ≤3 mL/min).
3. Wash Cartridge:
a) 1 × 3 mL D.I. H2O
b) 1 × 3 mL 100 mM acetic acid
c) Dry column under full vacuum or pressure for 10 min.
4. Elution:
a) 1 × 3 mL methanol containing 2% ammonium hydroxide (methanol:NH4OH, 98:2 v/v).
b) Evaporate the sample to dryness under a gentle stream of nitrogen.
c) Reconstitute in 100 µL 95:5 D.I. H2O:methanol and vortex for 1 min.
d) Transfer sample to autosampler vial containing a low volume insert.
Instrumental
LC–MS/MS: Thermo Scientific™ Dionex™ Ultimate™ 3000 UHPLC and TSQ Vantage™ (MS/MS)
Column: 100 × 2.1 mm, 3-μm UCT Selectra® DA HPLC column
Guard Column: 10 × 2.1 mm, 3-μm UCT Selectra® DA guard column
Injection Volume: 5 μL
Mobile Phase A: D.I. H2O 0.1% formic acid
Mobile Phase B: Methanol 0.1% formic acid
Column Flow Rate: 0.30 mL/min
Results
Conclusion
A fast and effective method was developed for the determination of six designer opiates in urine samples. All analytes of interest were extracted using a Clean Screen® XCEL I column. Analysis of the samples was performed by LC–MS/MS utilizing a Selectra® DA HPLC column, which allowed for improved separation of furanyl fentanyl and fentanyl, when compared to other column phases. Absolute recoveries ranged from 72.9–125.3% for all three control levels tested. With the unfortunate (and often unaware) abuse of synthetic opiates throughout the United States, it is critical that forensic laboratories have accurate and rapid SPE methods for the identification of this class of compounds. This method will be of great use as drugs with similar structures start to be found in casework.
UCT, LLC
2731 Bartram Road, Bristol, Pennsylvania 19007, USA
Tel: (800) 385 3153
E-mail: methods@unitedchem.com Website: www.unitedchem.com
AI and GenAI Applications to Help Optimize Purification and Yield of Antibodies From Plasma
October 31st 2024Deriving antibodies from plasma products involves several steps, typically starting from the collection of plasma and ending with the purification of the desired antibodies. These are: plasma collection; plasma pooling; fractionation; antibody purification; concentration and formulation; quality control; and packaging and storage. This process results in a purified antibody product that can be used for therapeutic purposes, diagnostic tests, or research. Each step is critical to ensure the safety, efficacy, and quality of the final product. Applications of AI/GenAI in many of these steps can significantly help in the optimization of purification and yield of the desired antibodies. Some specific use-cases are: selecting and optimizing plasma units for optimized plasma pooling; GenAI solution for enterprise search on internal knowledge portal; analysing and optimizing production batch profitability, inventory, yields; monitoring production batch key performance indicators for outlier identification; monitoring production equipment to predict maintenance events; and reducing quality control laboratory testing turnaround time.